• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氨氯地平与地尔硫䓬对接受β受体阻滞剂治疗的冠心病患者的电生理效应

Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy.

作者信息

Santarelli P, Biscione F, Natale A, Manzoli A, Lanza G A

机构信息

Institute of Cardiology, Catholic University, Rome, Italy.

出版信息

Cardiovasc Drugs Ther. 1994 Aug;8(4):653-8. doi: 10.1007/BF00877419.

DOI:10.1007/BF00877419
PMID:7848900
Abstract

This study compares the electrophysiologic effects of amlodipine and diltiazem in patients with coronary artery disease concomitantly treated with background beta-blocking therapy. Thirty patients were included in an open-label parallel study in two phases. During phase 1, patients were screened and placed on maintenance atenolol therapy at 50 or 100 mg/day, while phase 2 consisted of right-sided catheterization and randomization of patients to either amlodipine (10 mg i.v.) or diltiazem (10 mg i.v.). Following treatment with amlodipine, no significant alteration in markers of electrophysiological activity was observed. Treatment with diltiazem resulted in a significant lengthening of sinus cycle length (SCL, p < 0.04), AH interval (p < 0.02), and Wenckebach CL (WCL, p < 0.001), and a trend towards an increase in sinus node recovery time (SNRT, p = 0.057). No effects were observed with regard to HV interval and corrected SNRT. The results of this study indicate that 10 mg intravenous amlodipine has no significant electrophysiological action on sinus or AV node function in patients receiving beta-blocker therapy with atenolol, suggesting that amlodipine can be added to beta-blockers to treat patients with myocardial ischemia and/or hypertension without any significant increase in the risk of bradyarrhythmias.

摘要

本研究比较了氨氯地平和地尔硫䓬在接受背景β受体阻滞剂治疗的冠心病患者中的电生理效应。30名患者纳入一项开放标签的两阶段平行研究。在第1阶段,对患者进行筛查并给予阿替洛尔维持治疗,剂量为50或100毫克/天,而第2阶段包括右侧心导管检查,并将患者随机分为接受氨氯地平(静脉注射10毫克)或地尔硫䓬(静脉注射10毫克)治疗。给予氨氯地平治疗后,未观察到电生理活动标志物有明显改变。地尔硫䓬治疗导致窦性周期长度(SCL,p<0.04)、AH间期(p<0.02)和文氏周期长度(WCL,p<0.001)显著延长,且窦性结恢复时间(SNRT,p=0.057)有增加趋势。未观察到对HV间期和校正SNRT有影响。本研究结果表明,10毫克静脉注射氨氯地平对接受阿替洛尔β受体阻滞剂治疗的患者的窦房结或房室结功能无显著电生理作用,提示氨氯地平可添加到β受体阻滞剂中,用于治疗心肌缺血和/或高血压患者,而不会显著增加缓慢性心律失常的风险。

相似文献

1
Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy.氨氯地平与地尔硫䓬对接受β受体阻滞剂治疗的冠心病患者的电生理效应
Cardiovasc Drugs Ther. 1994 Aug;8(4):653-8. doi: 10.1007/BF00877419.
2
Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial.冠状动脉疾病中心肌缺血的药物治疗:CAPE II试验中药物治疗方案及不规律给药的影响
J Am Coll Cardiol. 2002 Sep 4;40(5):917-25. doi: 10.1016/s0735-1097(02)02050-8.
3
Electrophysiologic effects of oral diltiazem before and after beta blockade.β受体阻滞剂治疗前后口服地尔硫䓬的电生理效应
Clin Cardiol. 1991 Apr;14(4):317-20. doi: 10.1002/clc.4960140407.
4
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.雷诺嗪联合阿替洛尔、氨氯地平或地尔硫䓬对严重慢性心绞痛患者运动耐量和心绞痛发作频率的影响:一项随机对照试验。
JAMA. 2004 Jan 21;291(3):309-16. doi: 10.1001/jama.291.3.309.
5
Intracardiac electrophysiologic study of intravenous diltiazem and combined diltiazem-digoxin in patients.患者静脉注射地尔硫䓬及地尔硫䓬与地高辛联合用药的心脏内电生理研究。
Am Heart J. 1982 Jan;103(1):57-66. doi: 10.1016/0002-8703(82)90530-0.
6
Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators.氨氯地平与地尔硫䓬作为阿替洛尔的附加抗心绞痛治疗。欧洲心绞痛研究集中研究(CESAR)调查人员。
Am J Cardiol. 1998 Jan 15;81(2):133-6. doi: 10.1016/s0002-9149(97)00893-x.
7
Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.米贝拉地尔治疗系统性高血压:与其他钙拮抗剂的对比研究。
Am J Cardiol. 1997 Aug 21;80(4B):27C-33C. doi: 10.1016/s0002-9149(97)00567-5.
8
Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators.氨氯地平、阿替洛尔及其联合用药对平板运动及动态监测期间心肌缺血的影响。加拿大氨氯地平/阿替洛尔无症状性缺血研究(CASIS)调查组。
J Am Coll Cardiol. 1995 Mar 1;25(3):619-25. doi: 10.1016/0735-1097(94)00436-t.
9
Open comparative study to assess the efficacy and safety of two calcium antagonists: amlodipine and diltiazem in the treatment of symptomatic myocardial ischemia.开放比较研究以评估两种钙拮抗剂氨氯地平和地尔硫䓬治疗有症状心肌缺血的疗效和安全性。
J Cardiovasc Pharmacol. 1991;17 Suppl 1:S57-60. doi: 10.1097/00005344-199117001-00018.
10
Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.米贝拉地尔治疗慢性稳定型心绞痛:与其他钙拮抗剂的对比研究。
Am J Cardiol. 1997 Aug 21;80(4B):34C-39C. doi: 10.1016/s0002-9149(97)00568-7.

引用本文的文献

1
Cardiovascular outcomes of β-blocker-calcium channel blocker initial dual therapy vs. other initial dual therapies in Chinese patients with hypertension: A real-world retrospective study.β受体阻滞剂-钙通道阻滞剂初始双联治疗与其他初始双联治疗在我国高血压患者中的心血管结局比较:一项真实世界回顾性研究。
J Clin Hypertens (Greenwich). 2023 May;25(5):440-452. doi: 10.1111/jch.14665. Epub 2023 Apr 29.
2
Hyperinsulinemia euglycemia therapy for calcium channel blocker overdose: a case report.高胰岛素正常血糖疗法治疗钙通道阻滞剂过量:一例报告
Tex Heart Inst J. 2012;39(4):575-8.
3
Atrioventricular dissociation after electroconvulsive therapy.

本文引用的文献

1
An update on the safety of amlodipine.氨氯地平安全性的最新情况。
J Cardiovasc Pharmacol. 1991;17 Suppl 1:S65-8. doi: 10.1097/00005344-199117001-00020.
2
A 6-week double-blind comparison of amlodipine and placebo in patients with stable exertional angina pectoris receiving concomitant beta-blocker therapy.氨氯地平与安慰剂治疗稳定型劳力性心绞痛患者的6周双盲对照试验,这些患者同时接受β受体阻滞剂治疗。
J Cardiovasc Pharmacol. 1991;17 Suppl 1:S50-2. doi: 10.1097/00005344-199117001-00016.
3
Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.
电抽搐治疗后出现房室分离。
Cardiol Res Pract. 2011;2011:746373. doi: 10.4061/2011/746373. Epub 2011 Sep 15.
4
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.氨氯地平。对其药理特性及在心血管疾病治疗应用的重新评估。
Drugs. 1995 Sep;50(3):560-86. doi: 10.2165/00003495-199550030-00009.
钙通道阻滞剂的不同心血管效应:潜在机制
Am J Cardiol. 1982 Feb 18;49(3):499-506. doi: 10.1016/s0002-9149(82)80002-7.
4
Electrophysiologic mechanisms: sinus node dysfunction.电生理机制:窦房结功能障碍
Circulation. 1987 Apr;75(4 Pt 2):III12-8.
5
Amlodipine pharmacokinetics in healthy volunteers.氨氯地平在健康志愿者中的药代动力学。
J Clin Pharmacol. 1988 Nov;28(11):990-4. doi: 10.1002/j.1552-4604.1988.tb03119.x.
6
Endurance testing for evaluation of antianginal therapy with amlodipine, a calcium channel blocking agent.
J Am Coll Cardiol. 1988 Sep;12(3):791-6. doi: 10.1016/0735-1097(88)90323-3.
7
A haemodynamic dose finding study with a new slow-calcium channel blocker (amlodipine) in coronary artery disease.一项关于新型慢钙通道阻滞剂(氨氯地平)在冠状动脉疾病中的血流动力学剂量探索性研究。
Herz. 1986 Dec;11(6):351-8.
8
Calcium antagonists in cardiovascular disease.心血管疾病中的钙拮抗剂
Br J Clin Pract. 1989 Oct;43(10):369-79.
9
The hemodynamic properties of amlodipine in anesthetised and conscious dogs: comparison with nitrendipine and influence of beta-adrenergic blockade.氨氯地平在麻醉和清醒犬体内的血流动力学特性:与尼群地平的比较及β-肾上腺素能阻滞剂的影响
Cardiovasc Drugs Ther. 1989 Aug;3(4):545-55. doi: 10.1007/BF01865514.
10
The efficacy of amlodipine in myocardial ischemia.
Am Heart J. 1989 Nov;118(5 Pt 2):1123-6. doi: 10.1016/0002-8703(89)90840-5.